Notis McConarty Edward Acquires 1,424 Shares of Eli Lilly and Company $LLY

Key Points

• Notis McConarty Edward significantly increased its holdings in Eli Lilly and Company by 494.4%, acquiring an additional 1,424 shares in the second quarter, bringing its total ownership to 1,712 shares valued at approximately $1.34 million.
• In the second quarter, several institutional investors expanded their stakes in Eli Lilly, including PNC Financial Services and Cohen Investment Advisors, highlighting strong institutional interest with over 82% of the company's stock owned by institutional investors.
• Eli Lilly reported strong financial performance for the quarter ending August 7th, with an earnings per share of $6.31, surpassing estimates and achieving a revenue of $15.56 billion, reflecting a year-over-year increase of 37.6%.

Notis McConarty Edward increased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 494.4% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 1,712 shares of the company's stock after purchasing an additional 1,424 shares during the period. Notis McConarty Edward's holdings in Eli Lilly and Company were worth $1,335,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of LLY. PNC Financial Services Group Inc. grew its holdings in Eli Lilly and Company by 97.5% during the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock worth $83,669,349,000 after purchasing an additional 50,002,551 shares during the period. Nuveen LLC bought a new stake in shares of Eli Lilly and Company during the first quarter worth approximately $4,613,912,000. Vanguard Group Inc. boosted its holdings in shares of Eli Lilly and Company by 6.7% during the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock worth $65,432,218,000 after acquiring an additional 4,975,395 shares during the period. Cohen Investment Advisors LLC boosted its holdings in shares of Eli Lilly and Company by 7,975.5% during the first quarter. Cohen Investment Advisors LLC now owns 783,651 shares of the company's stock worth $647,225,000 after acquiring an additional 773,947 shares during the period. Finally, Assenagon Asset Management S.A. boosted its holdings in shares of Eli Lilly and Company by 106.8% during the second quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company's stock worth $1,154,508,000 after acquiring an additional 765,010 shares during the period. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 0.2%

Shares of LLY opened at $845.55 on Thursday. Eli Lilly and Company has a one year low of $623.78 and a one year high of $937.00. The company has a market cap of $800.28 billion, a P/E ratio of 55.26, a P/E/G ratio of 1.18 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a current ratio of 1.28 and a quick ratio of 1.00. The firm has a 50 day simple moving average of $738.69 and a two-hundred day simple moving average of $766.57.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the previous year, the business earned $3.92 earnings per share. The company's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, Director Jamere Jackson acquired 200 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, August 8th. The shares were bought at an average price of $639.56 per share, with a total value of $127,912.00. Following the completion of the purchase, the director directly owned 9,402 shares in the company, valued at $6,013,143.12. This trade represents a 2.17% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Gabrielle Sulzberger acquired 117 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the purchase, the director owned 2,703 shares of the company's stock, valued at $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on LLY shares. Daiwa America cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Sunday, August 17th. Weiss Ratings restated a "hold (c+)" rating on shares of Eli Lilly and Company in a report on Wednesday. Hsbc Global Res upgraded Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a report on Wednesday, August 27th. Leerink Partners restated a "market perform" rating and set a $715.00 price objective on shares of Eli Lilly and Company in a report on Thursday, August 7th. Finally, Morgan Stanley dropped their price target on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating for the company in a research report on Friday, October 3rd. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have given a Hold rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $943.00.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.